Elevated serum HMGB1 in pulmonary arterial hypertension secondary to congenital heart disease

Vascular Pharmacology

Volumn 85, Issue , 2016, Pages 66-72

  Huang, Yi yuan ^a   Su, Wei ^a,b   Zhu, Zhao wei ^a   Tang, Liang ^a   Hu, Xin qun ^a   Zhou, Sheng hua ^a   Fang, Zhen fei ^a   Li, Jiang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Biomarkers; Congenital malformations; HMGB1; Pulmonary hypertension

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH MOBILITY GROUP B1 PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITROGEN; SILDENAFIL; TRIACYLGLYCEROL; UREA; URIC ACID; BIOLOGICAL MARKER; HMGB1 PROTEIN, HUMAN; PHOSPHODIESTERASE V INHIBITOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERY BLOOD FLOW; ARTERY DIAMETER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONGENITAL HEART DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; ECHOCARDIOGRAPHY; EISENMENGER COMPLEX; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE TOLERANCE; FEMALE; FOLLOW UP; HEART LEFT RIGHT SHUNT; HEART RIGHT VENTRICLE PRESSURE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SENSITIVITY AND SPECIFICITY; SIX MINUTE WALK TEST; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; TRICUSPID VALVE REGURGITATION; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; VENOUS OXYGEN TENSION; BLOOD; CASE CONTROL STUDY; COMPLICATION; CONGENITAL HEART MALFORMATION; HYPERTENSION, PULMONARY; MIDDLE AGED; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASCULAR RESISTANCE; YOUNG ADULT;

ADULT; BIOMARKERS; CASE-CONTROL STUDIES; EISENMENGER COMPLEX; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART DEFECTS, CONGENITAL; HMGB1 PROTEIN; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SILDENAFIL CITRATE; TREATMENT OUTCOME; VASCULAR RESISTANCE; YOUNG ADULT;

EID: 84990026737     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2016.08.009     Document Type: Article

References (23)

1. [1] Rabinovitch, M., Haworth, S.G., Castaneda, A.R., et al. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation 58 (1978), 1107–1122.
2. [2] Vongpatanasin, W., Brickner, M.E., Hillis, L.D., et al. The Eisenmenger syndrome in adults. Ann. Intern. Med. 128 (1998), 745–755.
3. [3] D'Alto, M., Mahadevan, pulmonary arterial hypertension associated with congenital heart disease. Eur. Respir. Rev. 21 (2012), 328–337.
4. [4] Lopes, A., Alnajashi, K., Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: pulmonary arterial hypertension associated with congenital heart disease. Ann. Thorac. Med. 9 (2014), S21–S25.
5. [5] Galiè, N., Hoeper, M.M., Humbert, M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur. Heart J. 30 (2009), 2493–2537.
6. [6] Laaban, J.P., Diebold, B., Zelinski, R., et al. Noninvasive estimation of systolic pulmonary artery pressure using Doppler echocardiography in patients with chronic obstructive pulmonary disease. Chest 96 (1989), 1258–1262.
7. [7] Kyle, W.B., Pulmonary hypertension associated with congenital heart disease: a practical review for the pediatric cardiologist. Congenit. Heart Dis. 7 (2012), 575–583.
8. [8] Warwick, G., Thomas, P.S., Yates, D.H., Biomarkers in pulmonary hypertension. Eur. Respir. J. 32 (2008), 503–512.
9. [9] Foris, V., Kovacs, G., Tscherner, M., et al. Biomarkers in pulmonary hypertension: what do we know?. Chest 144 (2013), 274–283.
10. [10] Kang, R., Chen, R., Zhang, Q., et al. HMGB1 in health and disease. Mol. Asp. Med. 40 (2014), 1–116.
11. [11] Bauer, E.M., Shapiro, R., Zheng, H., et al. High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4. Mol. Med. 18 (2013), 1509–1518.
12. [12] Sadamura-Takenaka, Y., Ito, T., Noma, S., et al. HMGB1 promotes the development of pulmonary arterial hypertension in rats. PLoS One, 9, 2014, e102482, 10.1371/journal.pone.0102482 (eCollection 2014).
13. [13] Beghetti, M., Tissot, C., Pulmonary hypertension in congenital shunts. Rev. Esp. Cardiol. (Engl Ed) 63 (2010), 1179–1193.
14. [14] Krishnan, U., Rosenzweig, E.B., Pulmonary arterial hypertension associated with congenital heart disease. Clin. Chest Med. 34 (2013), 707–717.
15. [15] LaFarge, C.G., Miettinen, O.S., The estimation of oxygen consumption. Cardiovasc. Res. 4 (1970), 23–30.
16. [16] Vargo, T.A., Cardiac Catheterization: Hemodynamic Measurements. Garson, A., Bricker, J.T., Fisher, D.J., Neish, S.R., (eds.) The Science and Practice of Pediatric Cardiology, 2nd ed., 1998, Lippincott Williams & Wilkins, Baltimore, 961–993.
17. [17] Maugeri, N., Franchini, S., Campana, L., et al. Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis. Autoimmunity 45 (2012), 584–587.
18. [18] Bauer, E.M., Shapiro, R., Billiar, T.R., et al. High mobility group Box 1 inhibits human pulmonary artery endothelial cell migration via a Toll-like receptor 4- and interferon response factor 3-dependent mechanism(s). J. Biol. Chem. 288 (2013), 1365–1373.
19. [19] Sachdev, U., Cui, X., Hong, G., et al. High mobility group box 1 promotes endothelial cell angiogenic behavior in vitro and improves muscle perfusion in vivo in response to ischemic injury. J. Vasc. Surg. 55 (2012), 180–191.
20. [20] Singh, T.P., Rohit, M., Grover, A., et al. A randomized, placebocontrolled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am. Heart J., 151, 2006, 851.e1–5, 10.1016/j.ahj.2005.09.006.
21. [21] Chau, E.M., Fan, K.Y., Chow, W.H., Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int. J. Cardiol. 120 (2007), 301–305.
22. [22] Ikemoto, Y., Teraguchi, M., Takaya, J., et al. Plasma levels of nitric oxide products and endothelin in pulmonary hypertension with congenital heart disease. Acta Paediatr. 87 (1998), 715–716.
23. [23] Wang, L.J., Lu, L., Zhang, F.R., et al. Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. Eur. J. Heart Fail. 13 (2011), 440–449.